Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies:: A multivariate analysis

被引:62
作者
Carmona, F
Font, J
Azulay, M
Creus, M
Fábregues, F
Cervera, R
Puerto, B
Balasch, J
机构
[1] Univ Barcelona, Inst Invest Biomed, Hosp Clin, Inst Clin Gynecol Obstet & Neonatol, Barcelona 08036, Spain
[2] Univ Barcelona, Fac Med, Hosp Clin,System Autoimmune Dis Unit, Inst Invest Biomed August Pi & Sunyer, Barcelona 08036, Spain
关键词
antiphospholipid syndrome; pregnancies; fetal outcome; obstetric complications; risk factors;
D O I
10.1034/j.1600-0897.2001.d01-13.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
PROBLEM: Pregnancies in women with antiphospholipid syndrome (APS) are associated with obstetric complications despite treatment. The present study analyzes risk factors and evaluates fetal outcome in a large sample of treated APS pregnancies. METHOD OF STUDY: Seventy-seven pregnancies in 56 women were included. Twelve selected variables potentially related to the outcome of treated pregnancies were analyzed in a multivariate logistic regression model. RESULTS: Treated women delivered 65 live infants at 24-41 weeks gestation (mean 36.7 +/- 0.5) but two neonatal deaths occurred. There were seven first-trimester miscarriages (9%) and five intrauterine fetal demises (6.5%). Thus, the probability of having a live baby under treatment was 82% (95% CI 71.3-89.6%), a figure significantly greater (P<0.001) than that observed before therapy (25.7%; 95% CI 18.7-33.7%). Variables related with fetal outcome in the multivariate model were: preconceptional use of aspirin and abnormal umbilical artery Doppler velocimetry at 23-26 weeks gestation. CONCLUSIONS: The present report shows that in treated APS pregnancies: i) aspirin treatment started preconceptionally is an independent and significant prognostic factor associated with favorable fetal outcome; and ii) abnormal velocity waveforms in the umbilical artery predict adverse outcome of pregnancy.
引用
收藏
页码:274 / 279
页数:6
相关论文
共 22 条
[1]   Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin [J].
Backos, M ;
Rai, R ;
Baxter, N ;
Chilcott, IT ;
Cohen, H ;
Regan, L .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1999, 106 (02) :102-107
[2]  
Balasch J, 1996, HUM REPROD, V11, P2310
[3]   LOW-DOSE ASPIRIN FOR PREVENTION OF PREGNANCY LOSSES IN WOMEN WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME [J].
BALASCH, J ;
CARMONA, F ;
LOPEZSOTO, A ;
FONT, J ;
CREUS, M ;
FABREGUES, F ;
INGELMO, M ;
VANRELL, JA .
HUMAN REPRODUCTION, 1993, 8 (12) :2234-2239
[4]   ANTIPHOSPHOLIPID ANTIBODIES IN UNSELECTED PATIENTS WITH REPEATED ABORTION [J].
BALASCH, J ;
FONT, J ;
LOPEZSOTO, A ;
CERVERA, R ;
JOVE, I ;
CASALS, FJ ;
VANRELL, JA .
HUMAN REPRODUCTION, 1990, 5 (01) :43-46
[5]  
BALASCH J, 1996, ANTIPHOSPHOLIPID SYN, P299
[6]  
BRANCH DW, 1992, OBSTET GYNECOL, V80, P614
[7]   THOUGHTS ON THE MECHANISM OF PREGNANCY LOSS ASSOCIATED WITH THE ANTIPHOSPHOLIPID SYNDROME [J].
BRANCH, DW .
LUPUS, 1994, 3 (04) :275-280
[8]   Antiphospholipid antibodies in obstetrics: new complexities and sites of action [J].
Caruso, A ;
De Carolis, S ;
Di Simone, N .
HUMAN REPRODUCTION UPDATE, 1999, 5 (03) :267-276
[9]  
Coulam CB, 1999, AM J REPROD IMMUNOL, V41, P121
[10]   Prevention of fetal death in the antiphospholipid antibody syndrome [J].
Cowchock, S .
LUPUS, 1996, 5 (05) :467-472